Testosterone and Longevity in Men:
What the TRAVERSE Trial Finally Settled
(And What It Didn't)

The Testosterone Decline in Aging Men

Testosterone does not disappear suddenly — it erodes slowly, quietly, across decades. After approximately age 30, total testosterone falls at roughly 1–2% per year. By age 70, the average man has 30–40% less testosterone than he had at 25. By 80, the decline can exceed 50%.

This aggregate decline masks an even more complicated physiological shift. As men age, sex hormone-binding globulin (SHBG) — the protein that carries testosterone in the bloodstream — increases substantially. SHBG-bound testosterone is biologically inactive; only the fraction that is free or loosely bound to albumin can enter cells and exert hormonal effects. The result: even men with "normal" total testosterone by lab reference ranges may have meaningfully reduced free testosterone — the fraction that actually matters for muscle, libido, mood, cognition, and metabolic health.

Symptoms of Low Testosterone

The clinical presentation of testosterone deficiency is heterogeneous. No single symptom is diagnostic; the full constellation, combined with biochemical confirmation, is what defines treatable hypogonadism:

Reference Ranges and the "Normal" Problem

Most laboratory reference ranges define "normal" total testosterone as 300–1,000 ng/dL. This range was derived from population surveys of mostly younger men and has not been meaningfully age-adjusted by most clinical guidelines. The result is a reference range so wide as to be almost clinically useless.

The Endocrine Society defines hypogonadism as total testosterone below 300 ng/dL (consistently — at least two morning measurements), combined with symptoms. The American Urological Association uses a similar cutoff. However, multiple clinical experts argue that "functional hypogonadism" can occur at levels of 400–500 ng/dL in symptomatic men, particularly those with elevated SHBG reducing free testosterone.

Free testosterone (measured directly or calculated from total T and SHBG) may be a more clinically meaningful value. Many physicians who specialize in men's health use a free testosterone threshold of approximately 50–70 pg/mL as a functional lower limit, regardless of what the total testosterone shows.

The Cardiovascular Controversy: 2013–2022

For roughly a decade, the question of whether testosterone replacement therapy increases cardiovascular risk was medicine's loudest open argument in men's health. The controversy erupted from two influential observational studies:

• 2013 Vigen et al. (JAMA) reported that TRT was associated with increased rates of heart attack, stroke, and death in men with coronary disease. The study had significant methodological problems (including the bizarre finding that more women were in the TRT group than the control group, suggesting data errors) but generated enormous media coverage.
• 2014 Finkle et al. (PLOS ONE) suggested a doubling of MI risk in the 90 days following TRT initiation in older men. This, combined with the Vigen paper, prompted the FDA to add a black box warning to all testosterone products — requiring labeling that stated the risk of cardiovascular events.

TRT prescribing dropped substantially following these warnings. But subsequent research repeatedly contradicted the initial findings. Large database studies — the RHYME registry, multiple VA database analyses — found either no association or an inverse association between TRT and cardiovascular events. The hypothesis emerged that low testosterone itself was a cardiovascular risk factor, and that treating it might be protective.

The field desperately needed a randomized controlled trial. Observational studies were insufficient to untangle cause and effect: men who received TRT were different from those who didn't in dozens of ways that could confound cardiovascular outcomes. What followed was the TRAVERSE trial — the largest and most definitive RCT of TRT ever conducted.

The TRAVERSE Trial (NEJM 2023): What It Found

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of long-term Vascular Events and efficacy ResponSE) was published in the New England Journal of Medicine in 2023 (Lincoff AM et al.). It enrolled 5,198 men aged 40–85 years with hypogonadism (total testosterone below 300 ng/dL confirmed on two occasions) who had, or were at high risk for, cardiovascular disease. Participants were randomized to daily testosterone gel (targeting levels of 350–750 ng/dL) or placebo gel for a median of 33 months.

Primary Outcome: MACE (Cardiovascular Events)

The primary endpoint was the first occurrence of a major adverse cardiovascular event (MACE): death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke. The finding: TRT was non-inferior to placebo for MACE (hazard ratio 0.96, 95% CI 0.78–1.17). The upper confidence interval boundary fell below the pre-specified non-inferiority margin of 1.50. In practical terms: there is no evidence that testosterone gel increases heart attack, stroke, or cardiovascular death risk in hypogonadal men with cardiovascular risk factors.

What TRAVERSE Did Not Settle

The TRAVERSE trial answers the cardiovascular safety question for the specific population studied: middle-aged to older hypogonadal men with established or high-risk cardiovascular disease, using moderate-dose testosterone gel for approximately 3 years. Several questions remain open:

• →Long-term safety beyond 3 years is not established by this trial
• →Results may not generalize to injectable testosterone, pellets, or higher doses
• →Optimal total testosterone target within the normal range for longevity outcomes remains unknown
• →Effects in men without cardiovascular risk were not the focus of this study population

Metabolic Benefits: The Fat, Muscle, and Insulin Axis

One of testosterone's most metabolically important roles is its influence on body composition. Testosterone promotes muscle protein synthesis and inhibits adipogenesis — the formation of new fat cells — particularly in visceral fat depots. When testosterone falls in aging men, this regulation is disrupted in both directions simultaneously: muscle synthesis slows while visceral fat accumulation accelerates.

Visceral fat (the fat surrounding abdominal organs, as distinct from subcutaneous fat beneath the skin) is metabolically active in a damaging way: it secretes inflammatory cytokines, increases cortisol exposure, impairs insulin signaling, and directly correlates with cardiovascular and metabolic risk. The testosterone-visceral fat relationship is bidirectional: low testosterone promotes visceral fat accumulation, and visceral fat produces aromatase enzyme that converts testosterone to estradiol, further lowering testosterone.

Multiple RCTs have shown that TRT in hypogonadal men significantly reduces visceral fat and improves insulin sensitivity, HOMA-IR (a measure of insulin resistance), and HbA1c. The T-LIFE trial and several meta-analyses support TRT as a meaningful intervention for hypogonadal men with type 2 diabetes or metabolic syndrome — not merely for symptomatic benefit, but for actual glycemic control improvement.

The Longevity Signal: Low Testosterone and Mortality

Beyond its effects on symptoms and body composition, the question of whether hypogonadism increases mortality — and whether treating it extends life — is the central longevity question in male hormone medicine.

The most striking evidence comes from Muraleedharan et al. (2013, European Journal of Endocrinology), a UK-based study following 581 hypogonadal men with type 2 diabetes over 6.2 years. Men with total testosterone below 10.4 nmol/L (~300 ng/dL) had a 2.3-fold higher all-cause mortality rate compared to eugonadal (normal testosterone) men. Among those who received TRT, mortality normalized to rates comparable to eugonadal men. This was observational data, but the effect size was dramatic.

The most intellectually honest position: low testosterone in aging men is a marker associated with poor health outcomes, and treating it produces measurable improvements in body composition, metabolic parameters, and quality of life. Whether TRT extends lifespan directly, or simply improves the quality of the years remaining, remains an open research question. The TRAVERSE trial is the first step toward answering it definitively.

Prostate Safety: Debunking the Old Fear

For decades, the dominant concern about TRT was prostate cancer. The hypothesis, originating from Charles Huggins's Nobel Prize-winning work in the 1940s, was that testosterone "feeds" prostate cancer — because androgen deprivation therapy (ADT) is a well-established treatment for advanced prostate cancer. This led to a clinical dogma that giving testosterone to men with a history of prostate cancer, or even those at risk, was dangerous.

Abraham Morgentaler (Harvard Medical School) challenged this dogma with the "saturation model" (2006). His central argument: prostate tissue has a threshold of androgen sensitivity. Above a relatively low testosterone level (approximately 150–200 ng/dL), prostate cells are already at maximal androgen stimulation — adding more testosterone does not accelerate prostate cancer growth. This explains why supraphysiologic testosterone in healthy young men does not cause prostate cancer, while castrate levels in elderly men do not prevent it completely.

The TRAVERSE trial found no difference in prostate cancer incidence between TRT and placebo groups. Multiple meta-analyses of TRT trials have failed to find a significantly increased prostate cancer risk with physiologic testosterone replacement.

Practical implication: PSA testing before initiating TRT remains clinically appropriate. Active prostate cancer is still a relative contraindication. But the blanket fear that TRT causes prostate cancer in men without active disease is not supported by evidence.

TRT Delivery Methods: A Practical Guide

Optimizing Testosterone Naturally (Without TRT)

For men with low-normal or borderline testosterone who do not meet criteria for clinical hypogonadism, or who prefer to avoid exogenous hormones, several evidence-based lifestyle interventions can meaningfully raise testosterone:

The DHEA Precursor Alternative

DHEA (dehydroepiandrosterone) is a precursor steroid produced by the adrenal glands that can be peripherally converted to testosterone and estradiol. DHEA declines sharply with aging — a phenomenon called adrenopause. OTC DHEA supplements (25–50mg/day) can partially offset this decline. Effects on testosterone are modest and variable — peripheral conversion depends on individual enzyme activity and varies substantially between people. DHEA supplementation is not a substitute for TRT in true hypogonadism, but represents a lower-risk first step for men with borderline T levels and mild symptoms.

Natural Testosterone Support Protocol

Related Articles on LongevityLab

Key References